抗抑郁药治疗成人重度抑郁的QTc变化与早期主要心血管不良事件:个体参与者数据网络荟萃回归
该研究基于双盲随机试验的个体参与者数据网络荟萃回归和聚合配对荟萃分析,比较特定抗抑郁药与安慰剂对成人重度抑郁障碍治疗前8周QTc间期的影响,并探讨抗抑郁药使用与早期主要心血管不良事件(MACE)的关联。结果显示,艾司西酞普兰和阿米替林与QTc间期延长相关,但聚合分析未发现抗抑郁药使用与早期MACE及非自杀性死亡风险增加相关。
要点
- 艾司西酞普兰和阿米替林与QTc间期延长相关,需关注个体风险因素。
- 未发现抗抑郁药使用与早期MACE及非自杀性死亡风险增加相关。
- 选择抗抑郁药时应考虑可改变和不可改变的风险因素以支持共享决策。
核心结论
- 特定抗抑郁药对成人抑郁患者QTc间期的影响存在差异,未发现抗抑郁药使用与早期MACE及非自杀性猝死相关的证据。
主要发现
- 与安慰剂相比,艾司西酞普兰和阿米替林与QTc间期增加相关(分别为8.7毫秒,95%CrI 1.6至15.8;5.3毫秒,95%CrI 0.8至9.8)。
- 考虑风险因素时,阿米替林和艾司西酞普兰与最高QTc延长相关(分别为58.8%和21.3%),而文拉法辛和伏硫西汀常与最低QTc间期相关(分别为24.1%和9.7%)。
- 聚合分析未发现抗抑郁药使用与早期MACE及非自杀性死亡风险增加相关(风险差0.01%,95%CrI -0.01%至0.02%)。
关键数值与推荐
- 纳入标准为成人(≥18岁)重度抑郁障碍依据标准化操作化标准诊断的双盲随机试验。
临床怎么用
- 选择抗抑郁药时应考虑个体可改变和不可改变的风险因素,权衡获益与风险以支持共享决策。
局限性
- 仅35项(27%)试验提供个体水平QTc数据,可能限制个体水平分析的代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effect of specific antidepressants with placebo on heart rate corrected QT interval (QTc) during the first eight weeks of treatment for major depressive disorder in adults, and to investigate whether antidepressant use is associated with early major cardiovascular adverse events (MACE). DESIGN: Individual participant data (IPD) network meta-regression and aggregate pairwise meta-analysis. DATA SOURCES: Individual and aggregate level data from randomised controlled trials identified through Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS, Medline, Medline In-Process, PsycINFO, the websites of regulatory agencies, and international registers. METHODS: IPD were harmonised to enhance comparability and analysed using network meta-regressions to explore the interplay with baseline QTc, age, sex assigned at birth, body mass index, serum potassium level, and estimated glomerular filtration rate. The primary outcome was changes in QTc Fridericia (QTcF) associated with specific antidepressants and placebo after taking into account modifiable and non-modifiable risk factors. Aggregate data on early MACE were analysed using pairwise meta-analysis comparing antidepressants with placebo. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Double blind randomised trials of adults (≥18 years) with major depressive disorder diagnosed according to standardised, operationalised criteria. RESULTS: Of 130 unique randomised controlled trials identified, 35 (27%) included individual level data (8679 participants) on QTc with placebo and 10 antidepressants (amitriptyline, bupropion, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, trazodone, venlafaxine, vortioxetine). Compared with placebo, escitalopram and amitriptyline were associated with increased QTc intervals (8.7 milliseconds (ms), 95% credibility interval (CrI) 1.6 to 15.8, and 5.3 ms, 0.8 to 9.8, respectively). When risk factors were considered, amitriptyline and escitalopram were also associated with the highest QTc prolongations (58.8% and 21.3%, respectively), whereas venlafaxine and vortioxetine were often associated with the lowest QTc intervals (24.1% and 9.7%, respectively). Important variability of effects was observed, especially for escitalopram, fluoxetine, and mirtazapine. An aggregate analysis of 139 trials (52 398 participants) did not identify an association between antidepressant use and increased rates of early MACE and non-suicidal death compared with placebo (risk difference 0.01%, 95% CrI -0.01% to 0.02%). CONCLUSIONS: The effect of specific antidepressants on QTc interval differed between adults with depression. No evidence associated antidepressant use with early MACE and non-suicidal sudden death. To support shared decision making and taking into account the trade-off between benefits and harms, individual modifiable and non-modifiable risk factors should be considered when choosing antidepressants. SYSTEMATIC REVIEW REGISTRATION: Open Science Framework https://osf.io/c8k65/.
引用
- Ostinelli EG, Capocci S, Li Z, et al. QTc changes and early major adverse cardiovascular events associated with antidepressant treatment for major depressive disorder in adults: individual participant data network meta-regression of double blind randomised trials. BMJ. 2026. PMID: 42778211. doi:10.1136/bmj-2026-100600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。